Study Shows Decreased Enrollment of People with Advanced ILC vs. IDC in Interventional Clinical Trials

At this year’s ASCO, several abstracts and posters featuring invasive lobular carcinoma (ILC), also known as lobular breast cancer, were submitted. One study discussed the underrepresentation of patients with metastatic ILC in clinical trials. Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials was authored by Mary Kathryn Abel, AB, UCSF Medical Student; Rita A. Mukhtar, MD, Associate Professor of Surgery at UCSF and LBCA Scientific Advisor; and co-authored by Julia Katherine Levine, LBCA’s Lead Research Advocate among others.

To view the published abstract click here. To view the poster, click here.

The poster was also recommended as one of the featured abstracts from ASCO 2021  in Practice Update by Dr. Ben Anderson for Breast Cancer and Global Oncology. To read Dr. Anderson’s summary, click here.

Share this article:
Scroll to Top

Join Us

Subscribe for the Latest News & Updates​

  • This field is for validation purposes and should be left unchanged.